We’re speaking at the Global RWE & Market Access Summit 2025
15-16 October 2025
Leonardo Royal Hotel, Frankfurt, Germany
Book a meetingJoin us at the Global RWE Market Access Summit 2025, where this year’s theme explores “Precision in Practice: The Role of RWE in Modern Healthcare.” This essential gathering brings together market access professionals, health economists and industry leaders to examine how real-world evidence is transforming healthcare decision-making and patient outcomes.
With our deep expertise in European healthcare systems and proven track record of supporting successful market access strategies, Sciensus is excited to connect with partners who share our commitment to getting life-changing therapies to patients faster and more effectively across the complex European landscape.
Meet the Sciensus team at the Global RWE & Market Access Summit 2025
Our speaking session
Too Late to Generate: Why Early Evidence is a Commercial Imperative
Speakers: Andrew Cummins – VP, Business Development; Noolie Gregory – Head of Evidence Generation
Explore how…
- Early evidence generation drives commercial success and market access for rare therapies
- “Fit-for-purpose” evidence evolves across development stages and impacts key decisions
- Delays in planning evidence can affect pricing, partnerships and overall product value
Walk away with a clear understanding of why early, strategic evidence generation is critical, practical insights into aligning evidence with business development, pricing and HTA goals and actionable strategies to avoid value erosion caused by delayed planning.
Tuesday 16th October at 11:40am
Too Late to Generate: Why Early Evidence is a Commercial Imperative
Speakers: Andrew Cummins – VP, Business Development; Noolie Gregory – Head of Evidence Generation
Explore how…
- Early evidence generation drives commercial success and market access for rare therapies
- “Fit-for-purpose” evidence evolves across development stages and impacts key decisions
- Delays in planning evidence can affect pricing, partnerships and overall product value
Walk away with a clear understanding of why early, strategic evidence generation is critical, practical insights into aligning evidence with business development, pricing and HTA goals and actionable strategies to avoid value erosion caused by delayed planning.
Sciensus’ unique solution
Sciensus, sitting at the intersection of patients and their medications, is uniquely positioned to draw on 30 years of patient interactions across Europe to generate this crucial insight.
Every day we’re trusted to engage directly with patients, both in person and through digital solutions, enabling us to gather real-time, high-quality patient-reported data. This forms the backbone of our real-world evidence services.
Depending on your area of focus it might be that we have rich data that no-one else has that can generate unique insights. We can also reach patients for prospective data collection generating a dataset aligned to you needs.
Expertise that makes the difference
Leveraging over 30 years of clinical experience, deep therapeutic expertise and personalised digital innovation, we help biopharma, CROs and CCOs bring treatments to patients across Europe faster.
0 +
Years’ experience in Europe
0
patients supported each year
0 +
patient interactions
0 +
patients active on our apps
Get a faster route into Europe
Request a meeting for a focused strategic conversation on your asset, where we’ll explore how you can accelerate access to Europe by using one integrated partner for end-to-end support.